- Q3 2021 revenue up 21% (vs. Q3 2020) to €2.1 million
- Buoyant growth of 49% to €1.8 million in Spine activity in Q3
2021 (vs. Q3 2020) and +61% to €4.3 million over the first 9 months
of 2021 (vs. the same period in 2020)
A webinar will be held at 6 pm CEST today,
October 12, 2021:
https://us02web.zoom.us/webinar/register/WN_Oe6xOgujQbaeWbhPm-ISgw
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for
PEA-PME equity savings plans) (Paris:ALIMP) a medical technology
company specializing in vertebral and knee-surgery implants, today
announces its revenue for the third quarter and first nine months
of the year to September 30, 2021.
Ludovic Lastennet, IMPLANET’s CEO, said: “These
third-quarter results confirm our sales’ growth momentum since the
start of 2021, despite a health context and a shortage of hospital
staff that are still hindering a return to normal levels of
activity. While supporting this upturn by meeting surgeons’
expectations, we are continuing to refocus our business on Spine,
initiated with the acquisition of OSD in May. The project we
recently announced to divest our Knee business will allow IMPLANET
to establish itself as a benchmark player in spine surgery, both in
France and abroad, while consolidating its current financial
situation. Thanks to these additional resources, we will intensify
and accelerate our commercial development, enhance our range of
vertebral implants and continue to expand our certifications and
accreditations over the coming months”.
In € thousands - IFRS1
2021
2020
Change %
Total 1st quarter revenue
1,678
1,567
+7%
Total 2nd quarter revenue
2,040
1,028
+98%
3rd
quarter
Spine
1,775
1,194
+49%
Knee
336
555
-39%
Total 3rd quarter revenue
2,112
1,749
+21%
9-month
revenue
Spine
4,352
2,704
+61%
Knee
1,477
1,640
-10%
Total 9-month revenue
5,830
4,344
+34%
Third quarter of 2021
IMPLANET’s refocus on its Spine business and the integration of
OSD since May 19, 2021 helped the Company generate Q3 Spine revenue
growth of 49% compared with the same quarter of 2020.
In France, Spine activity doubled compared with the third
quarter of 2020 (and the same quarter of 2019), with sales totaling
€0.75 million. In the United States, the postponement of the
quarterly order from the Company’s partner, SeaSpine, and of
numerous surgeries addressed directly negatively impacted activity
over the period, with revenue falling 36% compared with the third
quarter of 2020, to €0.41 million. In the rest of the world,
revenue was multiplied by almost 3.5 compared with the same period
of 2020 (+235%) and by over 2.5 compared with 2019 (+160%), to
€0.62 million.
MADISONTM activity was down compared with the third quarter of
2020, at €0.34 million. This was primarily due to the public health
situation and the postponement of this type of surgery because of
human resources issues in healthcare facilities.
First nine months of
2021
In total, over the nine months to the end of September 2021,
IMPLANET recorded revenue of €5.83 million2, up 34% compared with
the first 9 months of 2020 and +5% compared with the same period of
2019.
Thanks to the acquisition of OSD in the first half of 2021,
Spine activity generated a buoyant 61% increase in revenue compared
with 2020, to €4.35 million. This activity was also up 22% compared
with 2019.
2021 highlights to date
- Agreement for the acquisition of OSD, which specializes in
developing, manufacturing and marketing implants for spine
surgery;
- Clearance for the MADISONTM total knee prosthesis obtained from
the TGA (Therapeutic Goods Administration) enabling the product to
be marketed in Australia;
- Signing of a strategic partnership with ulrich medical® for the
distribution of JAZZ® implants and the OSD cervical plate;
- Exclusive distribution contract with GLOBUS MEDICAL to market
the latter’s Scoliosis Correction System to 15 French university
centers specialized in pediatric spine surgery in order to increase
our market share;
- Planned divestment of the MADISONTM knee prosthesis business to
refocus on becoming a benchmark player in Spine surgery.
A webinar will be held at 6 pm CEST
today, October 12, 2021
The Company would like to inform its shareholders that a webinar
will be held at 6 pm (Paris time) today.
During this web conference, Ludovic Lastennet, Chief Executive
Officer, and David Dieumegard, Chief Financial Officer, will be at
your disposal to discuss:
- the improvement in 2021 half-year results;
- the revenue for the third quarter of 2021; - the planned
divestment of the MADISONTM knee prosthesis business; - and the
strategic axes of the development plan.
The webinar will be in French and will be followed by a Q&A
session. To follow this webinar, just log in via the following
link:
https://us02web.zoom.us/webinar/register/WN_Oe6xOgujQbaeWbhPm-ISgw
Upcoming financial event:
- 2021 annual revenue, January 18, 2022 after
market close*
* Date subject to modification
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its
activity revolves around two product ranges, a comprehensive
innovative solution for improving the treatment of spinal
pathologies (JAZZ® and OSD), as well as the MADISON implant for
first-line prosthetic knee surgery. Implanet’s tried-and-tested
orthopedic platform is based on the traceability of its products.
Protected by four families of international patents, JAZZ® has
obtained 510(k) regulatory clearance from the Food and Drug
Administration (FDA) in the United States, the CE mark in Europe
and ANVISA approval in Brazil. IMPLANET employs 29 staff and
recorded sales of €6.0 million in 2020. For further information,
please visit www.implanet.com. Based near Bordeaux in France,
IMPLANET opened a US subsidiary in Boston in 2013. In May 2021,
IMPLANET acquired Orthopaedic & Spine Development (OSD), which
specializes in developing, manufacturing and marketing implants for
spine surgery and offers a product range that complements the
latest generation JAZZ® implant (thoraco-lumbar screws, cages and
cervical plates). IMPLANET is listed on the Euronext Growth market
in Paris.
The Company would like to remind readers that the table for
monitoring the equity line (OCA, BSA) and the number of shares
outstanding is available on its website:
http://www.implanet-invest.com/suivi-des-actions-80
1 Unaudited data
2 Since May 19, 2021, Spine activity includes revenue recorded
by OSD, i.e. €1.17 million.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005793/en/
IMPLANET Ludovic Lastennet, CEO David Dieumegard, CFO
Tel.: +33 (0)5 57 99 55 55 investors@Implanet.com
NewCap Investor Relations Mathilde Bohin Nicolas Fossiez
Tel.: +33 (0)1 44 71 94 94 implanet@newcap.eu
NewCap Media Relations Nicolas Merigeau Tel.: +33 (0)1 44
71 94 94 implanet@newcap.eu
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Implanet (EU:ALIMP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024